More molecularly driven nccRCC classifications has been further recognized in the 2022 WHO classification, including ELOC (TCEB1)-mutated RCC, ALK-rearranged RCC and SMARCB1-deficient medullary RCC [2,3]. This evidence concerns the gene SMARCB1 and renal cell carcinoma.